

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bachmann *et al.*

Appl. No.: *To be assigned* (U.S. Natl.
Phase of PCT/EP2004/005208)

Filing Date: (Int'l Filing Date: May 14, 2004)

For: **Selection of B Cells with Specificity of
Interest: Method of Preparation and Use**

Confirmation No.: *To be assigned*

Art Unit: *To be assigned*

Examiner: *To be assigned*

Atty. Docket: 1700.0420001/BJD/SJE

Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms PTO-1449 and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents AL1 to AM1 and NPL1 to NPL6 are submitted. A copy of document AA1, U.S. Patent No. 5,326,696, is not submitted. 37 C.F.R. § 1.98(a)(2).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

10/556904

JC12 Rec'd PCT/USC 15 NOV 2005

- 2 -

Bachmann *et al.*

Appl. No. *To be assigned*

(U.S. Natl. Phase of PCT/EP2004/005208)

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed within three months of the date of filing. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Simon J. Elliott, Ph.D.
Agent for Applicants
Registration No. 54,083

Date: November 15, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

458506_1.DOC

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 1700.0420001/BJD/SJE	APPLICATION NO. <i>To Be Assigned</i> (U.S. Natl. Phase of PCT/EP2004/005208; Int'l Filing Date: May 14, 2004)		
				FIRST NAMED INVENTOR Bachmann et al.			
				FILING DATE: I.A. Date: May 14, 2004	ART UNIT <i>To be assigned</i>		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	5,326,696	07/05/1994	Chang, Tse W.			02/17/1993
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 2004/102198 A3	11/25/2004	WIPO			Yes No
	AM1	WO 03/024481 A2	03/27/2003	WIPO			Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	1					
	AS	1					
	AT	1					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

10/556904

JC12 Rec'd PCT/EP 15 NOV 2005

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	To Be Assigned (U.S. Natl. Phase of PCT/EP2004/005208; Int'l Filing Date: May 14, 2004)
Sheet	1	of	1	First Named Inventor	Bachmann <i>et al.</i>
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	1700.0420001/BJD/SJE

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published		T ²
	NPL1	Bachmann, M.F. and Zinkernagel, R.M., "The influence of virus structure on antibody responses and virus serotype formation," <i>Immunol. Today</i> 17:553-558, Elsevier Science Publishers (1996)		
	NPL2	Benhar, I., "Biotechnological applications of phage and cell display," <i>Biotechnol. Adv.</i> 19:1-33, Elsevier Science Inc. (2001)		
	NPL3	Fehr, T., <i>et al.</i> , "T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles," <i>Proc. Natl. Acad. Sci. USA</i> 95:9477-9481, National Academy of Sciences (1998)		
	NPL4	Jegerlehner, A., <i>et al.</i> , "A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses," <i>Vaccine</i> 20:3104-3112, Elsevier Science Ltd. (August, 2002)		
	NPL5	Vasiljeva, I., <i>et al.</i> , "Mosaic Q β coats as a new presentation model," <i>FEBS Lett.</i> 431:7-11, Federation of European Biochemical Societies (1998)		
	NPL6	Weitkamp, J.-H., <i>et al.</i> , "Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles," <i>J. Immunol. Meth.</i> 275:223-237, Elsevier Science B.V. (April, 2003)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.